SUO 2019: Novel Systemic Therapies in Penile Cancer
SUO 2019 novel systemic therapies in penile cancer, neoadjuvant chemotherapy for penile squamous cell cancer (PSCC), immune checkpoint blockade therapy,
Related Articles
PRIMARY Score and Where it Plays a Role in Prostate Cancer Diagnosis “Presentation” – Michael Hofman
At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman presents the PRIMARY score for PSMA PET in prostate cancer diagnosis. He explains how PSMA PET complements…
Selecting Patients for Triplet Therapy in Metastatic Prostate Cancer – Oliver Sartor
Zachary Klaassen speaks with Oliver Sartor about treatment intensification in metastatic hormone-sensitive prostate cancer, focusing on triplet therapy selection. Dr. Sartor traces the evolution from…
Advanced Imaging for Focal Therapy in Intermediate Risk Prostate Cancer – Matthew Cooperberg
Zachary Klaassen speaks with Matthew Cooperberg about the integration of OnQ™ Prostate assisted Focal One® Robotic HIFU for prostate cancer treatment. Dr. Cooperberg discusses how…
Real-World Evidence Informs Clinical Decision-Making in Metastatic Castration-Resistant Prostate Cancer – Alan Bryce
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alan…
Combining Alpha and Beta Emitters in PSMA-Targeted Prostate Cancer Therapy – Scott Tagawa
Pedro Barata interviews Scott Tagawa about radioligand therapy research, focusing on actinium-225 PSMA antibody constructs. Dr. Tagawa explains that antibodies like rosopatamab offer advantages over…
Sequencing with RLT in mCRPC “Presentation” – Tanya Dorff
At the 2025 UCSF-UCLA PSMA Conference, Tanya Dorff addresses treatment sequencing in advanced prostate cancer. She notes PARP inhibitors show superior efficacy when used early…
Post-VISION Real World Experience in the US: How is PSMA RLT Being Used? “Presentation” – Matthew Rettig
At the 2025 UCSF-UCLA PSMA Conference, Matthew Rettig discusses real-world PSMA radioligand therapy usage in the VA healthcare system. He highlights VA patients are older…
Lessons from Germany in Early Access PSMA Therapy in Clinical Practice “Presentation” – Wolfgang Fendler
At the 2025 UCSF-UCLA PSMA Conference, Wolfgang Fendler discusses German early access programs for lutetium-PSMA therapy. He highlights five key contributions: actinium-PSMA alpha therapy data;…
Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management – Oliver Sartor
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: A.…
ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions – Nimira Alimohamed
Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current…